A recent systematic review on neoadjuvant EGFR-TKI therapy for EGFR-mutant NSCLC concluded that this provides a feasible treatment modality with satisfactory surgical outcomes and low toxicity [49]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.